Overview

A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
To determine if subjects with steroid refractory cGVHD can tolerate imatinib mesylate and whether their cGVHD responds to imatinib mesylate.
Phase:
Phase 1
Details
Lead Sponsor:
David Miklos
Stanford University
Collaborator:
Novartis
Treatments:
Imatinib Mesylate